Christopher Durant Turner, Chief Medical Officer at Nuvalent, Inc. (NUVL), sold 8,032 shares at $80.54 ($640K) on 2025-01-06, disclosed to the SEC on 2025-01-08.
Scheduled sale ($640k) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $78.28 | 1,152 | $90K | 14.1% |
| 2 | $78.28 | 1,152 | $90K | 14.1% |
| 3 | $79.33 | 691 | $55K | 8.6% |
| 4 | $79.33 | 691 | $55K | 8.6% |
| 5 | $80.54 | 2,173 | $175K | 27.3% |
| 6 | $80.54 | 2,173 |
| $175K |
| 27.3% |
| Total | $79.68 avg | 8,032 | $640K | 100% |
| Filing → |
| NUVL | SELL | 2023-07-28 | $482K | — | Filing → |
| NUVL | SELL | 2023-07-24 | $14K | — | Filing → |
| NUVL | SELL | 2023-06-07 | $918K | — | Filing → |